Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus Adefovir

NCT03236584 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Proportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48

Interventions

DRUG: lamivudine plus adefovir combination
DRUG: Tenofovir Disoproxil Fumarate

Sponsor

Uijeongbu St. Mary Hospital